Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05856656 Not yet recruiting - Breast Cancer Clinical Trials

Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer

CENSORIAL
Start date: September 2023
Phase: N/A
Study type: Interventional

Breast cancer is the number one cancer in women worldwide, with 58,500 new cases in metropolitan France in 2018. The announcement of the cancer, the treatment methods and their side effects can generate unpleasant emotions, such as fear, for example, and the resources for coping with them differ according to the patient. Coming to the hospital as an outpatient for chemotherapy is in itself a source of anxiety. The use of music in the treatment process is a therapy that can help patients to reduce the intensity of their unpleasant emotions. Active music therapy involves the patient playing an instrument, including voice and body movement in rhythm, without requiring any musical skills. The presence of a qualified music therapy professional is essential, particularly in the reception of the emotions that may be generated during the sessions. These sessions can be collective or individual. In breast cancer, music therapy has been shown to be effective in reducing pain, anxiety, depressive symptoms and length of hospitalisation in patients undergoing mastectomy.

NCT ID: NCT05853848 Recruiting - Breast Cancer Clinical Trials

Mammogram Mail- and Phone-based Interventions

Start date: May 10, 2023
Phase: N/A
Study type: Interventional

The project aims to evaluate four different versions and modalities of interventions encouraging mammogram screening among all eligible women due or overdue for screening. The evaluation will compare among the following forms of outreach to help determine whether (a) live calls are more effective at increasing mammogram screening than other forms of outreach and (b) each form of outreach is more effective than no outreach: (1) a postcard, (2) a letter, (3) an auto-dialer phone message, and (4) a live call from a care gaps team. The interventions will be rolled out over many months, allowing for comparisons of effectiveness against those who have not yet been contacted.

NCT ID: NCT05852691 Recruiting - Breast Cancer Clinical Trials

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).

NCT ID: NCT05851677 Recruiting - Breast Cancer Clinical Trials

RC48-ADC in Breast Cancer

Start date: June 1, 2023
Phase:
Study type: Observational

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

NCT ID: NCT05851014 Recruiting - Breast Cancer Clinical Trials

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Start date: January 14, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy

NCT ID: NCT05850637 Completed - Clinical trials for Breast Cancer Female

Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer

Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.

NCT ID: NCT05848856 Not yet recruiting - Breast Cancer Risk Clinical Trials

The RISC Registry--Risk Informed Screening Registry

RISC
Start date: June 1, 2023
Phase:
Study type: Observational

Health inequities are defined as systemic differences in the health status of different population groups. It is well established that there are many sources of health inequity in oncology including differences in mortality, cancer screening uptake, time to diagnosis and disparities in access to treatment and care. Routine cancer screening and effective surveillance and follow up are some of the most effective ways to reduce the burden of cancer across an individual's lifetime and at the population level. While there is a lack of screening tests for many cancers, breast cancer, the second highest leading cause of cancer death in women, has a plethora of validated screening and risk reduction approaches which can yield earlier detection and effective ways of treating and following women at risk and with breast cancer and improve outcomes. However, there is uneven adoption and inconsistent use of these technologies and care practices. The RISC Registry is an observational study that seeks to understand the application of risk-informed screening and care approaches and pursue the hypothesis that these screening approaches accompanied by population appropriate methods of clinician and patient engagement may increase understanding and compliance with screening, surveillance and follow up recommendations by empowering people to make healthier choices, and support addressing disparities in screening and patient care. The primary focus is cancer screening with a focus on Precision Screening. (Precision Screening attempts to separate those who will benefit from screening from those that may not, through use of information on disease risk.) The study will start by focusing on women and breast cancer risk.

NCT ID: NCT05848739 Recruiting - Ovarian Cancer Clinical Trials

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Start date: June 5, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

NCT ID: NCT05848141 Recruiting - Clinical trials for Breast Cancer Survivors

Rowing Following Breast Cancer Chemotherapy

Start date: February 26, 2024
Phase: N/A
Study type: Interventional

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

NCT ID: NCT05846997 Recruiting - Breast Cancer Clinical Trials

Use of INnovative and Micro-INvasive TEchniques for the Early Identification of Breast Cancer Patients Benefitting From Neo-adjuvant Therapy

INTENT
Start date: June 20, 2018
Phase:
Study type: Observational

The purpose of the study is the identification of novel micro-invasive predictors of pathological complete response (pCR) during neo-adjuvant therapy